effect overlay
activetrials
Multiple sclerosis
Multiple Sclerosis
Fentrepid

A phase III multicenter, randomized,double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of fenebrutinib compared with ocrelizumab in adult patients with primary  progressive multiple sclerosis
 

HREC: 2020.082
Principal Investigator: Dr Mark Marriott
Coordinator contact: Katherine Fazzolari
Funding: Commercial
Multiple sclerosis
Multiple Sclerosis
SARS-CoV2 antibody-seroprevalence in MS

SARS-CoV2 antibody-seroprevalence in patients with multiple sclerosis
 

HREC: 2020.305
Principal Investigator: Dr Chris Dwyer
Coordinator contact:
Funding: Non-Commercial
Multiple sclerosis
Multiple Sclerosis
Meteroid

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab as Monotherapy or in Addition to Baseline Therapy in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
 

HREC: 2022.014
Principal Investigator: Dr Ai-Lan Nguyen
Coordinator contact: Hasini Fernando
Funding: Non-Commercial
Multiple sclerosis
Multiple Sclerosis
B-cell Repopulation

B-cell repopulation in patients with multiple sclerosis treated with anti-CD20 therapies
 

HREC: 2023.079
Principal Investigator: Prof Tomas Kalincik
Coordinator contact:
Funding: Non-Commercial
Multiple sclerosis
Multiple Sclerosis
ANZ NMO Collaboration

Prevalence and incidence study of neuromyelitis optica in Australia and New Zealand with population based sensitivity and specificity of NMO IgG antibody positivity
 

HREC: 2010.278
Principal Investigator: Dr Mark Marriott
Coordinator contact:
Funding: Non-Commercial